Immunocore Holdings plc’s (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc (NASDAQ:IMCR) shareholders have had their patience rewarded with a 27% share price jump in the last month. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 11% in the last twelve months.
Although its price has surged higher, Immunocore Holdings may still be sending buy signals at present with its price-to-sales (or “P/S”) ratio of 5.4x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.6x and even P/S higher than 53x aren’t out of the ordinary. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
